• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

采用 NMR 光谱法研究多价 V 治疗性蛋白的蛋白-赋形剂相互作用。

Investigating protein-excipient interactions of a multivalent V therapeutic protein using NMR spectroscopy.

机构信息

Sterile and Specialty Products, Merck & Co Inc, Kenilworth, NJ (United States).

Mass Spectrometry and Biophysics, Merck & Co Inc, Kenilworth, NJ United States.

出版信息

MAbs. 2022 Jan-Dec;14(1):2124902. doi: 10.1080/19420862.2022.2124902.

DOI:10.1080/19420862.2022.2124902
PMID:36166705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9519013/
Abstract

Fab Fragment antigen-binding; Fc Fragment crystallizable; HMW High molecular weight; ∆HMW Difference between HMW species at stress temperature and 5°C controls; IgG Immunoglobulin G; mAbs Monoclonal antibodies; MV-V Multivalent V molecule with the format aC-L-aC-L-aD; NMR Nuclear magnetic resonance; scFv Single-chain fragment variable; SEC Size-exclusion chromatography; V Variable domain of Heavy chain of Heavy chain-only antibody.

摘要

Fab 片段抗原结合；Fc 片段结晶；HMW 高分子量；∆HMW 在应激温度和 5°C 对照下 HMW 种间的差异；IgG 免疫球蛋白 G；mAbs 单克隆抗体；MV-V 多价 V 分子，形式为 aC-L-aC-L-aD；NMR 核磁共振；scFv 单链片段可变；SEC 尺寸排阻色谱；VH 重链的可变域，重链单克隆抗体。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/c80c47ffe0ed/KMAB_A_2124902_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/2e8bbe6e5b5e/KMAB_A_2124902_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/4833e0a79bda/KMAB_A_2124902_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/ba9f033c5991/KMAB_A_2124902_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/f2f501727cc2/KMAB_A_2124902_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/57246250eabb/KMAB_A_2124902_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/24a7250e774c/KMAB_A_2124902_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/bd2a46ebc805/KMAB_A_2124902_F0007_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/c80c47ffe0ed/KMAB_A_2124902_F0008_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/2e8bbe6e5b5e/KMAB_A_2124902_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/4833e0a79bda/KMAB_A_2124902_F0002_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/ba9f033c5991/KMAB_A_2124902_F0003_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/f2f501727cc2/KMAB_A_2124902_F0004_OC.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/57246250eabb/KMAB_A_2124902_F0005_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/24a7250e774c/KMAB_A_2124902_F0006_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/bd2a46ebc805/KMAB_A_2124902_F0007_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/df40/9519013/c80c47ffe0ed/KMAB_A_2124902_F0008_OC.jpg

相似文献

1
Investigating protein-excipient interactions of a multivalent V therapeutic protein using NMR spectroscopy.采用 NMR 光谱法研究多价 V 治疗性蛋白的蛋白-赋形剂相互作用。
MAbs. 2022 Jan-Dec;14(1):2124902. doi: 10.1080/19420862.2022.2124902.
2
Full-length recombinant antibodies from : production, characterization, effector function (Fc) engineering, and clinical evaluation.全长重组抗体：生产、表征、效应功能（Fc）工程和临床评估。
MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748.
3
Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.人源 IgG1 和 IgG4 S228P 单克隆抗体的黏度和自身相互作用的差异：结构域相互作用的实验评估和计算预测。
MAbs. 2021 Jan-Dec;13(1):1991256. doi: 10.1080/19420862.2021.1991256.
4
Titration calorimetry study of an anti-idiotypic antibody cascade in a human melanoma-associated antigen system.人黑色素瘤相关抗原系统中抗独特型抗体级联反应的滴定热分析研究
Mol Immunol. 1997 Jul;34(10):695-707. doi: 10.1016/s0161-5890(97)00095-3.
5
The eIg technology to generate Ig-like bispecific antibodies.利用 eIg 技术生成 Ig 样双特异性抗体。
MAbs. 2022 Jan-Dec;14(1):2063043. doi: 10.1080/19420862.2022.2063043.
6
Effect of Polysorbate 20 and Polysorbate 80 on the Higher-Order Structure of a Monoclonal Antibody and Its Fab and Fc Fragments Probed Using 2D Nuclear Magnetic Resonance Spectroscopy.用二维核磁共振波谱法研究聚山梨酯 20 和聚山梨酯 80 对单克隆抗体及其 Fab 和 Fc 片段高级结构的影响。
J Pharm Sci. 2017 Dec;106(12):3486-3498. doi: 10.1016/j.xphs.2017.08.011. Epub 2017 Aug 24.
7
Induced refolding of a temperature denatured llama heavy-chain antibody fragment by its antigen.其抗原诱导温度变性的羊驼重链抗体片段复性
Proteins. 2005 May 15;59(3):555-64. doi: 10.1002/prot.20378.
8
The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: a study by X-ray and neutron solution scattering and homology modelling.IgA1的Fab和Fc片段呈现出与IgG不同的排列方式：一项通过X射线和中子溶液散射以及同源建模的研究。
J Mol Biol. 1999 Mar 12;286(5):1421-47. doi: 10.1006/jmbi.1998.2556.
9
Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen.鼠单克隆抗体针对人高分子量黑色素瘤相关抗原不同决定簇的全免疫球蛋白及Fab'片段的结合参数和独特型谱。
Cancer Res. 1992 May 1;52(9):2497-503.
10
Introduction to heavy chain antibodies and derived Nanobodies.重链抗体及衍生纳米抗体简介。
Methods Mol Biol. 2012;911:15-26. doi: 10.1007/978-1-61779-968-6_2.

引用本文的文献

1
Mechanistic and predictive formulation development for viscosity mitigation of high-concentration biotherapeutics.高浓度生物治疗药物粘度降低的机理和预测配方开发。
MAbs. 2025 Dec;17(1):2550757. doi: 10.1080/19420862.2025.2550757. Epub 2025 Sep 15.

本文引用的文献

1
Utility of High Resolution 2D NMR Fingerprinting in Assessing Viscosity of Therapeutic Monoclonal Antibodies.高分辨 2D NMR 指纹图谱在评估治疗性单克隆抗体黏度中的应用。
Pharm Res. 2022 Mar;39(3):529-539. doi: 10.1007/s11095-022-03200-6. Epub 2022 Feb 16.
2
Principal Component Analysis of 1D 1H Diffusion Edited NMR Spectra of Protein Therapeutics.一维 1H 扩散编辑 NMR 谱的主成分分析在蛋白治疗药物中的应用。
J Pharm Sci. 2021 Oct;110(10):3385-3394. doi: 10.1016/j.xphs.2021.06.027. Epub 2021 Jun 21.
3
Comprehensive Assessment of Protein and Excipient Stability in Biopharmaceutical Formulations Using H NMR Spectroscopy.
使用核磁共振氢谱对生物制药制剂中的蛋白质和辅料稳定性进行综合评估。
ACS Pharmacol Transl Sci. 2020 Dec 16;4(1):288-295. doi: 10.1021/acsptsci.0c00188. eCollection 2021 Feb 12.
4
Nanobody Engineering: Toward Next Generation Immunotherapies and Immunoimaging of Cancer.纳米抗体工程：迈向癌症的下一代免疫疗法和免疫成像
Antibodies (Basel). 2019 Jan 21;8(1):13. doi: 10.3390/antib8010013.
5
NMR Assessment of Therapeutic Peptides and Proteins: Correlations That Reveal Interactions and Motions.NMR 评估治疗性肽和蛋白质：揭示相互作用和运动的相关性。
Chembiochem. 2020 Feb 3;21(3):315-319. doi: 10.1002/cbic.201900296. Epub 2019 Oct 24.
6
Understanding the Role of Preferential Exclusion of Sugars and Polyols from Native State IgG1 Monoclonal Antibodies and its Effect on Aggregation and Reversible Self-Association.理解天然状态 IgG1 单克隆抗体中糖和多元醇的优先排除作用及其对聚集和可逆自组装的影响。
Pharm Res. 2019 May 24;36(8):109. doi: 10.1007/s11095-019-2642-3.
7
In Situ Quantification of Polysorbate in Pharmaceutical Samples of Therapeutic Proteins by Hydrodynamic Profiling by NMR Spectroscopy.通过 NMR 光谱的流体动力学剖析对治疗性蛋白的药物样本中的聚山梨酯进行原位定量。
Anal Chem. 2019 Jun 18;91(12):7807-7811. doi: 10.1021/acs.analchem.9b01442. Epub 2019 Jun 4.
8
Diffusion Profiling of Therapeutic Proteins by Using Solution NMR Spectroscopy.利用溶液核磁共振波谱技术对治疗性蛋白质进行扩散分析。
Chembiochem. 2019 Apr 1;20(7):896-899. doi: 10.1002/cbic.201800631. Epub 2019 Mar 4.
9
SWISS-MODEL: homology modelling of protein structures and complexes.SWISS-MODEL：蛋白质结构和复合物的同源建模。
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303. doi: 10.1093/nar/gky427.
10
Impact of Buffer, Protein Concentration and Sucrose Addition on the Aggregation and Particle Formation during Freezing and Thawing.缓冲液、蛋白浓度和蔗糖添加对冷冻和解冻过程中聚集和颗粒形成的影响。
Pharm Res. 2018 Mar 19;35(5):101. doi: 10.1007/s11095-018-2378-5.